Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HyPeR: Guadecitabine/ASTX727 + Pembrolizumab in Refractory Solid Tumours
NCT02998567Phase 1Active, not recruiting
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jan 2017
- Primary completion
- Sep 2026
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of guadecitabine in solid tumor and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Maximum Tolerated Dose at 12 months and Adverse Events at 24 months. Started Jan 2017; status: active, not recruiting.
02
Drugs
guadecitabine
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02998567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998567.